Noting that from 1998 to 2017 there were about 146 failed shots at developing drugs for Alzheimer’s disease, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a report on the state of the industry.

As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials took four experimental vaccines to the front lines and began to administer it to patients who may have been exposed to the deadly virus.

In 2014, the U.S. National Institutes of Health launched a program called the Undiagnosed Disease Network. The New England Journal of Medicine published a study looking at the results of the network.

Britain’s Consort Medical Plc agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.

A nonprofit organization, Knowledge Ecology International (KEI), recently filed a lawsuit against the National Institutes of Health (NIH) over Gilead Sciences’ patents for a new chimeric antigen receptor T-cell (CAR-T) therapy.

Regeneron Pharmaceuticals Inc. announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project the company believes could help accelerate new drug discovery and improve approval success rates.

U.S. congressional committee members warned that Washington’s funding of the World Health Organization’s cancer research agency could be halted unless it is more open about its operations.

A filing with the U.S. Securities and Exchange Commission (SEC) indicates that the UK’s GlaxoSmithKline has a 13 percent stake in Spero Therapeutics, with 1,854,006 shares in the Massachusetts biotech company.

The U.S. government is investing more than $170 million to help two new vaccines against Ebola and two Ebola drugs complete the steps needed for FDA approval.

The U.S. Senate voted overwhelmingly to support sweeping legislation that will reshape the way the Food and Drug Administration approves new medicines.